Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2015 - 2026)

Syndax Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 120.49% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 120.49% increase from a year earlier, with the FY2025 full-year figure at $721000.0, up 71.26% from the prior year.
• Other Accumulated Expenses rose to $1.3 million in Q1 2026 per SNDX's latest filing, from $721000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.2 million in Q3 2022 and bottomed at $208000.0 in Q3 2024.
• The 5-year median for Other Accumulated Expenses is $703000.0 (2023), against an average of $1.0 million.
• Across the five-year window, Other Accumulated Expenses surged 1594.68% in 2022 and sank 83.13% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $604000.0 in 2022, then soared by 47.02% to $888000.0 in 2023, then plunged by 52.59% to $421000.0 in 2024, then jumped by 71.26% to $721000.0 in 2025, then soared by 76.14% to $1.3 million in 2026.
• Per Business Quant, the three latest SNDX Other Accumulated Expenses figures stand at $1.3 million (Q1 2026), $721000.0 (Q4 2025), and $595000.0 (Q3 2025).